Navigation Links
Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17
Date:6/15/2010

CARLSBAD, Calif., June 15 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it will conduct the fourth and last of this series of conference calls focused on the drugs in Isis' development pipeline.  The last call of the series will focus on Isis' neurodegenerative franchise and will be held on Thursday, June 17, 2010 at 12:00 p.m. ET.  This call will be archived for a limited time on Isis' Web site.

Isis has conducted three earlier calls that highlighted its cardiovascular, metabolic and cancer franchises.  The last call of the series will focus on Isis' neurodegenerative franchise as well as some of the other promising programs Isis and its partners are developing.  

Conference Call

At 12:00 p.m. Eastern Time Thursday, June 17, 2010, Isis will conduct a live webcast conference call.  Interested parties may listen to the call by dialing 866-831-6247 and refer to passcode "ISIS 2010" or access the webcast at www.isispharm.com.  A webcast replay will be available for a limited time at the same address.  

Isis' Neurodegenerative Franchise

Isis is pursuing the discovery and development of antisense drugs for neurodegenerative diseases in which there is a large unmet need for new treatment options.  Isis' initial goal is to develop ant
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... announces the launch of their 2nd generation cell therapy POD® design. The 2nd ... but it also represents a new POD® design. , “G-CON first offered ...
(Date:7/29/2015)... -- AmnioChor Inc., an early stage biotech startup based on ... that the Musculoskeletal Transplant Foundation of Edison ... seed round of development of the proprietary AmnioCept™ product ... AmnioChor,s technology allows cryopreservation of the amniotic membrane ... within those tissues. Amnion is a well-established source of ...
(Date:7/29/2015)... , July 29, 2015  Indivior PLC (LON: ... for naloxone nasal spray was accepted and received Priority ... for the treatment of opioid overdose. This naloxone nasal ... specially formulated for optimal absorption into the nasal mucosa. ... minimal training so individuals may be better equipped to ...
(Date:7/29/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... an optimized Erk inhibitor molecule for development, thus ... a new class of potential cancer therapies. ... target for therapeutic intervention in cancer. Recently approved ... for B-Raf and Mek inhibitors. Erk inhibitors may ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... Imagine an LED light with 20 times the efficiency ... transmit, and store data 100 times faster than those we ... we could turn waste heat into electricity, or improve the ... more accessible? The (IEE) at the University of ...
... Inc., a company dedicated to advancing orthopedic care ... that it has secured a $2M investment from ... chairman of Liberty Media Corporation. In addition to ... research, the investment will help support the national ...
... 2012   USHIFU, LLC (US HIFU), a world leader ... technologies, announced today that Mark Carol, MD, has ... officer. With more than 25 years of clinical ... will focus on continued development of the company,s ...
Cached Biology Technology:Oracle chairman Jeff Henley makes $50 million gift to UC Santa Barbara 2Oracle chairman Jeff Henley makes $50 million gift to UC Santa Barbara 3Oracle chairman Jeff Henley makes $50 million gift to UC Santa Barbara 4Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives 2US HIFU Adds Mark Carol, MD, As Chief Development Officer 2US HIFU Adds Mark Carol, MD, As Chief Development Officer 3US HIFU Adds Mark Carol, MD, As Chief Development Officer 4
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
(Date:7/7/2015)... , June 30, 2015 ... announced the addition of the "Capacitive Fingerprint ... To this date, fingerprint sensing technology ... and fingerprint sensors are well developed. This patent ... technology. The domain of capacitive fingerprint ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... MUHC have announced Quebec's first successful combined heart/liver transplant. ... from the Institut de cardiologie de Quebec (l'hôpital Laval) ... and liver during a 6-hour operation on April 14, ... procedure involved 15 physicians, surgeons and other health care ...
... used hybridization to transfer useful traits between species. ... aid? In a new study in the June ... University and Rice University), Rebecca A. Randell (Indiana ... how spontaneous hybridization ?known as adaptive trait introgression ...
... astonishing ability to apparently transform into any kind of cell ... with their surroundings - even when they are outside of ... report. , Using an animal model of embryonic stem cell ... answer one of the most fundamental questions in science - ...
Cached Biology News:MUHC announces a transplant first in Quebec 2Medium is the message for stem cells in search of identities 2Medium is the message for stem cells in search of identities 3
... Insect Cell Medium are recommended for protein ... combination has been selected based on rapid, ... levels observed specifically with baculoviruses derived from ... Ready-Plaque Sf9 Cells and BacVector Insect Cell ...
...
...
...
Biology Products: